慢性乙型肝炎患者中丁型肝炎病毒共感染的筛查与治疗研究进展

摘要/Abstract

摘要： 慢性乙型肝炎病毒(HBV)和丁型肝炎病毒(HDV)共感染对全球公共卫生构成重大威胁。HDV需要HBsAg蛋白质进入肝细胞,共感染通常是最严重的病毒性肝炎形式。共感染患者面临更高的肝硬化、肝功能失代偿和肝细胞癌风险,因此早期识别和诊断至关重要。HDV RNA阳性患者面临更高的肝相关并发症风险,且需要更复杂的治疗策略。提高HDV筛查覆盖率和接受度、制定综合治疗策略及加强政策制定者和公共卫生部门的参与,是应对HDV共感染的关键。本文探讨了HDV共感染的临床学意义、检测方法、治疗策略以及应对策略与政策建议,旨在为优化公共卫生政策提供科学依据。

关键词: 丁型肝炎病毒, 乙型肝炎病毒, 肝硬化, 筛查策略, 综合治疗

余姣, 万谟彬. 慢性乙型肝炎患者中丁型肝炎病毒共感染的筛查与治疗研究进展[J]. 肝脏, 2024, 29(7): 762-766.

/ 推荐

参考文献

[1] Alfaiate D, Lucifora J, Abeywickrama-Samarakoon N,et al. HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes[J]. Antiviral Res,2016, 136:19-31.
[2] Fu W, Deng ZW, Wang P, et al. A complex case study: coexistence of multi-drug-resistant pulmonary tuberculosis, HBV-related liver failure, and disseminated cryptococcal infection in an AIDS patient[J]. BMC Infect Dis 2024, 24(1):533.
[3] Carpentier A. Cell Culture Models for Hepatitis B and D Viruses Infection: Old Challenges, New Developments and Future Strategies[J]. Viruses 2024, 16(5):716.
[4] Wang Y, Shen G, Lu R, et al. The prevalence of HDV among HBsAg-positive populations with and without HIV-1 in China[J]. Int J Infect Dis, 2024,140:70-77.
[5] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus[J]. J Hepatol ,2023, 79(2):433-460.
[6] Roulot D, Brichler S, Layese R, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta[J]. J Hepatol 2020, 73(5):1046-1062.
[7] Kamal H, Westman G, Falconer K, et al. Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes[J]. Hepatology,2020, 72(4):1177-1190.
[8] Xu L, Xu Y, Zhang F, et al. Immunological pathways in viral hepatitis-induced hepato-cellular carcinoma[J]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2024, 53(1):64-72.
[9] Wedemeyer H, Leus M, Battersby TR, et al. HDV RNA assays: Performance characteristics, clinical utility, and challenges[J]. Hepatology 2023.
[10] Hayashi T, Takeshita Y, Hutin YJ, et al. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response[J]? Arch Public Health 2021, 79(1):180.
[11] Liu Y, Maya S, Carver S, et al. Development of a dual channel detection system for pan-genotypic simultaneous quantification of hepatitis B and delta viruses[J]. Emerg Microbes Infect 2024, 13(1):2350167.
[12] Weichselbaum L, Njimi H, van den Wijngaert S, et al. A regular screening for hepatitis delta virus among chronic hepatitis B carriers improves the diagnostic of this infection and of subsequent cirrhosis development[J]. United European Gastroenterol J, 2024, 12(4):516-525.
[13] Lampertico P, Degasperi E, Sandmann L, et al. Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022[J]. JHEP Rep,2023, 5(9):100818.
[14] Ghany MG, Buti M, Lampertico P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference[J]. J Hepatol, 2023, 79(5):1254-1269.
[15] Gish RG, Wong RJ, Di Tanna GL, et al. Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis[J]. Hepatology,023, 79(5):1129-1140.
[16] Nathani R, Leibowitz R, Giri D, et al. The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection[J]. J Viral Hepat,2022, 30(3):195-200.
[17] Kushner T, Serper M, Kaplan DE . Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes[J]. J Hepatol,2015, 63(3):586-592.
[18] Palom A, Rando-Segura A, Vico J, et al. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D[J]. JHEP Rep,2022, 4(10):100547.
[19] Patel EU, Thio CL, Boon D, et al. Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016[J]. Clin Infect Dis,2019, 69(4):709-712.
[20] Da BL, Rahman F, Lai WC, et al. Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened[J]? Am J Gastroenterol 2020, 116(1):206-209.
[21] Nathani R, Leibowitz R, Giri D, et al. Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B-coinfected adults in care in the United States[J]. J Viral Hepat 2023, 30(3):195-200.